Related Experiment Videos
Nesiritide: a novel approach for acute heart failure
Aungkana Vichiendilokkul1, Alison Tran, Eric Racine
1Cardiothoracic Surgery, Harper University Hospital, Detroit Medical Center, Detroit, MI 48201-2097, USA. avichien@dmc.org
The Annals of Pharmacotherapy
|January 29, 2003
Summary
Nesiritide, a B-type natriuretic peptide, effectively treats acutely decompensated heart failure by improving hemodynamics and symptoms. It offers an alternative for patients unresponsive to other treatments, with a favorable safety profile compared to nitroglycerin.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Acutely decompensated heart failure (ADHF) presents significant clinical challenges.
- Current ADHF management involves vasodilators, inotropes, and diuretics, with varying efficacy and side effects.
Purpose of the Study:
- To review preclinical and clinical data on nesiritide for ADHF treatment.
- To evaluate nesiritide's efficacy, safety, and role in ADHF management.
Main Methods:
- Comprehensive literature search of MEDLINE and secondary sources (1966-May 2002).
- Inclusion of peer-reviewed articles and randomized clinical trial abstracts in humans.
- Analysis of Food and Drug Administration (FDA) New Drug Application documents for nesiritide.
Main Results:
- Nesiritide demonstrates beneficial effects including vasodilation, natriuresis, and neurohormonal suppression.
- Significant improvements in hemodynamic parameters (e.g., pulmonary capillary wedge pressure) and clinical symptoms observed in ADHF patients.
- Nesiritide showed faster hemodynamic improvement and fewer adverse effects than intravenous nitroglycerin, with comparable hypotension rates.
Conclusions:
- Nesiritide provides a valuable alternative for ADHF management.
- Considered for patients refractory to other therapies or at high risk for arrhythmias.
- Further pharmacoeconomic research on nesiritide is recommended.